These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31062482)

  • 1. Back signaling of HLA class I molecules and T/NK cell receptor ligands in epithelial cells reflects the rejection-specific microenvironment in renal allograft biopsies.
    Egelkamp J; Chichelnitskiy E; Kühne JF; Wandrer F; Daemen K; Keil J; Bräsen JH; Schmitz J; Bellmàs-Sanz R; Iordanidis S; Katsirntaki K; Hake K; Akhdar A; Neudörfl C; Haller H; Blume C; Falk CS
    Am J Transplant; 2019 Oct; 19(10):2692-2704. PubMed ID: 31062482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
    Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
    Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation.
    Luque S; Lúcia M; Melilli E; Lefaucheur C; Crespo M; Loupy A; Bernal-Casas D; Gomà M; Jarque M; Crespo E; Montero N; Manonelles A; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
    Am J Transplant; 2019 Feb; 19(2):368-380. PubMed ID: 30085394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.
    Littera R; Piredda G; Argiolas D; Lai S; Congeddu E; Ragatzu P; Melis M; Carta E; Michittu MB; Valentini D; Cappai L; Porcella R; Alba F; Serra M; Loi V; Maddi R; Orrù S; La Nasa G; Caocci G; Cusano R; Arras M; Frongia M; Pani A; Carcassi C
    PLoS One; 2017; 12(7):e0180831. PubMed ID: 28686681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
    Eskandary F; Jilma B; Mühlbacher J; Wahrmann M; Regele H; Kozakowski N; Firbas C; Panicker S; Parry GC; Gilbert JC; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Apr; 18(4):916-926. PubMed ID: 28980446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
    Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
    Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and pathological significance of borderline T cell-mediated rejection.
    Nankivell BJ; Agrawal N; Sharma A; Taverniti A; P'Ng CH; Shingde M; Wong G; Chapman JR
    Am J Transplant; 2019 May; 19(5):1452-1463. PubMed ID: 30501008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor Specificity but Not Broadness of Sensitization Is Associated With Antibody-Mediated Rejection and Graft Loss in Renal Allograft Recipients.
    Wehmeier C; Hönger G; Cun H; Amico P; Hirt-Minkowski P; Georgalis A; Hopfer H; Dickenmann M; Steiger J; Schaub S
    Am J Transplant; 2017 Aug; 17(8):2092-2102. PubMed ID: 28245084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR.
    Parkes MD; Halloran PF; Hidalgo LG
    Am J Transplant; 2018 Jan; 18(1):63-73. PubMed ID: 28654216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation.
    Diebold M; Vietzen H; Heinzel A; Haindl S; Herz CT; Mayer K; Doberer K; Kainz A; Faé I; Wenda S; Kühner LM; Berger SM; Puchhammer-Stöckl E; Kozakowski N; Schaub S; Halloran PF; Böhmig GA
    Am J Transplant; 2024 May; 24(5):743-754. PubMed ID: 38097018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
    Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
    Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.
    Yazdani S; Callemeyn J; Gazut S; Lerut E; de Loor H; Wevers M; Heylen L; Saison C; Koenig A; Thaunat O; Thorrez L; Kuypers D; Sprangers B; Noël LH; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
    Kidney Int; 2019 Jan; 95(1):188-198. PubMed ID: 30396694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
    Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
    Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients.
    Comoli P; Cioni M; Tagliamacco A; Quartuccio G; Innocente A; Fontana I; Trivelli A; Magnasco A; Nocco A; Klersy C; Rubert L; Ramondetta M; Zecca M; Garibotto G; Ghiggeri GM; Cardillo M; Nocera A; Ginevri F
    Am J Transplant; 2016 Jul; 16(7):2106-16. PubMed ID: 26725780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.
    Schinstock CA; Cosio F; Cheungpasitporn W; Dadhania DM; Everly MJ; Samaniego-Picota MD; Cornell L; Stegall MD
    Am J Transplant; 2017 Jun; 17(6):1574-1584. PubMed ID: 27977905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up.
    Rabant M; Boullenger F; Gnemmi V; Pellé G; Glowacki F; Hertig A; Brocheriou I; Suberbielle C; Taupin JL; Anglicheau D; Legendre C; Duong Van Huyen JP; Buob D
    Am J Transplant; 2018 Apr; 18(4):972-981. PubMed ID: 29206350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants.
    Halloran PF; Merino Lopez M; Barreto Pereira A
    Am J Transplant; 2016 Mar; 16(3):908-20. PubMed ID: 26743766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
    Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
    J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.